IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treatment of invasive fungal infection in China
Wang Aixia1; Zhang Yingyuan1; He Lixian1; Shen Zhixiang1; Liao Wanqing1; Han Mingzhe1; Li Ruoyu1; Liang Derong1; Wu Shaoxi1; Corinna, Hahn-Ast1; Axel, Glasmacher1; Albert, Liekwok Wai1
刊名JAPANESE JOURNAL OF INFECTIOUS DISEASES
2006-12-01
59期:6页:370-376
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Infectious Diseases
研究领域[WOS]Infectious Diseases
关键词[WOS]EMPIRICAL ANTIFUNGAL THERAPY ; AMPHOTERICIN-B ; NEUTROPENIC PATIENTS ; ORAL ITRACONAZOLE ; IMMUNOCOMPROMISED PATIENTS ; HEMATOLOGIC MALIGNANCIES ; CRYPTOCOCCUS-NEOFORMANS ; PERSISTENT FEVER ; ASPERGILLOSIS ; EPIDEMIOLOGY
英文摘要

Itraconazole has a broad spectrum of activity against the most common fungal pathogens. Prior problems with absorption in severely ill patients have been overcome with the introduction of an oral solution and an intravenous preparation. An open-labeled, non-competitive, multicenter phase IV study was conducted to investigate the efficacy and safety of itraconazole administered intravenously for the treatment of invasive fungal infections in Chinese patients. Patients were treated with itraconazole intravenously for 2 weeks (200 mg twice daily for 2 days, then 200 mg once daily for 12 days) followed by 28 days of oral capsules (200 mg twice daily). Efficacy evaluation included an assessment of the clinical efficacy, fungal efficacy and total efficacy on days 14 and 42. Of 156 evaluable patients, 35 patients had proven and 62 suspected invasive fungal infections, and 59 patients were treated empirically. On day 14 the total efficacy rate in patients with proven infection was 54.3% (19/35; 95% confidence interval [CI], 37-71%) and on day 42 it was 65.7% (23/35; 95% CI, 48-81%). The most common adverse events were hypokalemia (13.5%), gastrointestinal disorders, (12.8%), elevation of liver enzymes (10.9%) and increase of bilirubin (8.3%). Itraconazole intravenously followed by oral capsules is thus tolerated and effective in severely ill patients with proven invasive fungal infection.

语种英语
WOS记录号WOS:000243318100005
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51011
专题北京大学第一临床医学院
作者单位1.Univ Bonn, Dept Internal Med 1, D-5300 Bonn, Germany
2.Peking Univ, First Hosp, Beijing 100871, Peoples R China
3.Fu Dan Univ, Zhongshan Hosp, Shanghai, Peoples R China
4.Chinese Acad Sci, Inst Dermatol, Nanjing, Peoples R China
5.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China
6.Fu Dan Univ, Huashan Hosp, Inst Antibiot, Shanghai, Peoples R China
7.Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China
8.Second Mil Med Univ, Changzheng Hosp, Shanghai, Peoples R China
9.Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
10.Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
11.Sichuan Univ, W China Hosp, W China Med Sch, Chengdu 610064, Peoples R China
12.Univ Hong Kong, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
推荐引用方式
GB/T 7714
Wang Aixia,Zhang Yingyuan,He Lixian,et al. Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treatment of invasive fungal infection in China[J]. JAPANESE JOURNAL OF INFECTIOUS DISEASES,2006,59(6):370-376.
APA Wang Aixia.,Zhang Yingyuan.,He Lixian.,Shen Zhixiang.,Liao Wanqing.,...&Albert, Liekwok Wai.(2006).Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treatment of invasive fungal infection in China.JAPANESE JOURNAL OF INFECTIOUS DISEASES,59(6),370-376.
MLA Wang Aixia,et al."Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treatment of invasive fungal infection in China".JAPANESE JOURNAL OF INFECTIOUS DISEASES 59.6(2006):370-376.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang Aixia]的文章
[Zhang Yingyuan]的文章
[He Lixian]的文章
百度学术
百度学术中相似的文章
[Wang Aixia]的文章
[Zhang Yingyuan]的文章
[He Lixian]的文章
必应学术
必应学术中相似的文章
[Wang Aixia]的文章
[Zhang Yingyuan]的文章
[He Lixian]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。